Securities code: 600062 securities abbreviation: China Resources Double-Crane Pharmaceutical Co.Ltd(600062) Announcement No.: pro 2022-010 China Resources Double-Crane Pharmaceutical Co.Ltd(600062)
Announcement on the approval of the restricted stock incentive plan by the state owned assets supervision and Administration Commission of the State Council
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents.
Recently, China Resources Double-Crane Pharmaceutical Co.Ltd(600062) (hereinafter referred to as “the company”) received the reply of the state owned assets supervision and Administration Commission of the State Council on the implementation of the restricted stock incentive plan for China Resources Double-Crane Pharmaceutical Co.Ltd(600062) (Guo Zi kaofen [2022] No. 44) forwarded by China Resources (Group) Co., Ltd. and the state owned assets supervision and Administration Commission of the State Council agreed in principle to the company’s implementation of the restricted stock incentive plan.
Matters related to this restricted stock incentive plan of the company need to be submitted to the general meeting of shareholders for deliberation and approval before implementation. The company will actively promote relevant work and timely fulfill the obligation of information disclosure in strict accordance with the company law, the securities law, the measures for the administration of equity incentives of listed companies and other relevant provisions.
It is hereby announced.
China Resources Double-Crane Pharmaceutical Co.Ltd(600062) board of directors
February 11, 2022
